Psyence Group Inc. (PSYGF)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 5.16 Million CAD | -13.48% |
| 2023 | 5.96 Million CAD | 32.34% |
| 2022 | 4.5 Million CAD | 4773.3% |
| 2021 | 92.51 Thousand CAD | 385.47% |
| 2020 | 19.05 Thousand CAD | -58.41% |
| 2019 | 45.82 Thousand CAD | 129.51% |
| 2018 | 19.96 Thousand CAD | -63.56% |
| 2017 | 54.78 Thousand CAD | 272.92% |
| 2016 | 14.69 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 5.16 Million CAD | -13.48% |
| 2024 Q4 | 1.69 Million CAD | 101.18% |
| 2024 Q3 | 841.93 Thousand CAD | 102.61% |
| 2024 Q2 | 415.53 Thousand CAD | -81.2% |
| 2024 Q1 | 2.21 Million CAD | -19.93% |
| 2023 Q3 | 1.08 Million CAD | 10.44% |
| 2023 Q4 | 2.76 Million CAD | 154.79% |
| 2023 Q1 | 1.14 Million CAD | 9.41% |
| 2023 FY | 5.96 Million CAD | 32.34% |
| 2023 Q2 | 981.22 Thousand CAD | -13.95% |
| 2022 FY | 4.5 Million CAD | 4773.3% |
| 2022 Q3 | 1.2 Million CAD | 13.09% |
| 2022 Q2 | 1.06 Million CAD | -10.96% |
| 2022 Q1 | 1.19 Million CAD | -89.85% |
| 2022 Q4 | 1.04 Million CAD | -13.48% |
| 2021 FY | 92.51 Thousand CAD | 385.47% |
| 2021 Q4 | 11.78 Million CAD | 16047.89% |
| 2021 Q2 | 7625.00 CAD | -86.29% |
| 2021 Q3 | 72.98 Thousand CAD | 857.11% |
| 2021 Q1 | 55.6 Thousand CAD | 0.0% |
| 2020 FY | 19.05 Thousand CAD | -58.41% |
| 2019 FY | 45.82 Thousand CAD | 129.51% |
| 2018 FY | 19.96 Thousand CAD | -63.56% |
| 2017 FY | 54.78 Thousand CAD | 272.92% |
| 2016 FY | 14.69 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AstraZeneca PLC | 29.57 Billion USD | 99.983% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | 99.97% |
| CSPC Pharmaceutical Group Limited | 2.14 Billion USD | 99.76% |
| Clarus Therapeutics Holdings, Inc. | 50.96 Million USD | 89.872% |
| Novartis AG | 24.87 Billion USD | 99.979% |
| PT Kalbe Farma Tbk. | 11823.24 Billion USD | 100.0% |